Orion Oyj

Symbol: ORNBV.HE

HEL

36.4

EUR

Market price today

  • 23.5728

    P/E Ratio

  • 0.5202

    PEG Ratio

  • 5.08B

    MRK Cap

  • 0.02%

    DIV Yield

Orion Oyj (ORNBV-HE) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.55%

Operating Profit Margin

0.20%

Net Profit Margin

0.18%

Return on Assets

0.15%

Return on Equity

0.27%

Return on Capital Employed

0.24%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Dr. Liisa Hurme
Full-time employees:3698
City:Espoo
Address:Orionintie 1A
IPO:2004-10-07
CIK:

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

General Outlook

When we look at how much money they make before expenses, they keep 0.551% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.196%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.178%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.148% return, is a testament to Orion Oyj's adeptness in optimizing resource deployment. Orion Oyj's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.270%. Furthermore, the proficiency of Orion Oyj in capital utilization is underscored by a remarkable 0.242% return on capital employed.

Stock Prices

Orion Oyj's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $36.65, while its low point bottomed out at $36.04. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Orion Oyj's stock market.

Liquidity Ratios

Analyzing ORNBV.HE liquidity ratios reveals its financial health of the firm. The current ratio of 178.17% gauges short-term asset coverage for liabilities. The quick ratio (100.23%) assesses immediate liquidity, while the cash ratio (39.57%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio178.17%
Quick Ratio100.23%
Cash Ratio39.57%

Profitability Ratios

ORNBV.HE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 22.25% underscores its earnings before tax deductions. The effective tax rate stands at 20.29%, revealing its tax efficiency. The net income per EBT, 79.82%, and the EBT per EBIT, 113.74%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 19.57%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin22.25%
Effective Tax Rate20.29%
Net Income per EBT79.82%
EBT per EBIT113.74%
EBIT per Revenue19.57%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.78, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding100
Days of Inventory Outstanding247
Operating Cycle333.03
Days of Payables Outstanding56
Cash Conversion Cycle277
Receivables Turnover4.23
Payables Turnover6.54
Inventory Turnover1.48
Fixed Asset Turnover3.04
Asset Turnover0.84

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.60, and free cash flow per share, 1.00, depict cash generation on a per-share basis. The cash per share value, 1.34, showcases liquidity position. A payout ratio of 0.19 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.18, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.60
Free Cash Flow per Share1.00
Cash per Share1.34
Payout Ratio0.19
Operating Cash Flow Sales Ratio0.18
Free Cash Flow to Operating Cash Flow Ratio0.62
Cash Flow Coverage Ratio1.16
Short Term Coverage Ratio7.65
Capital Expenditure Coverage Ratio2.66
Dividend Paid and Capex Coverage Ratio1.78
Dividend Payout Ratio0.04

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 13.32%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.28, we discern the balance between debt and equity financing. The long-term debt to capitalization, 18.93%, and total debt to capitalization, 21.57%, ratios shed light on its capital structure. An interest coverage of 62.84 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio13.32%
Debt Equity Ratio0.28
Long Term Debt to Capitalization18.93%
Total Debt to Capitalization21.57%
Interest Coverage62.84
Cash Flow to Debt Ratio1.16
Company Equity Multiplier2.06

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 8.48, provides a glimpse into top-line earnings distributed across each share. Net income per share, 1.54, reflects the portion of profit attributed to each share. The book value per share, 6.34, represents the net asset value distributed per share, while the tangible book value per share, 4.92, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share8.48
Net Income Per Share1.54
Book Value Per Share6.34
Tangible Book Value Per Share4.92
Shareholders Equity Per Share6.34
Interest Debt Per Share1.45
Capex Per Share-0.83

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -11.26%, indicates top-line expansion, while the gross profit growth, -22.52%, reveals profitability trends. EBIT growth, -47.38%, and operating income growth, -47.38%, offer insights into operational profitability progression. The net income growth, -37.97%, showcases bottom-line expansion, and the EPS growth, -37.75%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-11.26%
Gross Profit Growth-22.52%
EBIT Growth-47.38%
Operating Income Growth-47.38%
Net Income Growth-37.97%
EPS Growth-37.75%
EPS Diluted Growth-38.15%
Weighted Average Shares Growth-0.12%
Weighted Average Shares Diluted Growth-0.16%
Dividends per Share Growth6.62%
Operating Cash Flow Growth-72.61%
Free Cash Flow Growth-99.39%
10-Year Revenue Growth per Share18.73%
5-Year Revenue Growth per Share22.02%
3-Year Revenue Growth per Share10.49%
10-Year Operating CF Growth per Share-44.43%
5-Year Operating CF Growth per Share-48.33%
3-Year Operating CF Growth per Share-60.16%
10-Year Net Income Growth per Share5.65%
5-Year Net Income Growth per Share-34.20%
3-Year Net Income Growth per Share-1.28%
10-Year Shareholders Equity Growth per Share74.04%
5-Year Shareholders Equity Growth per Share15.42%
3-Year Shareholders Equity Growth per Share21.87%
10-Year Dividend per Share Growth per Share23.02%
5-Year Dividend per Share Growth per Share10.57%
3-Year Dividend per Share Growth per Share6.67%
Receivables Growth54.66%
Inventory Growth14.77%
Asset Growth-4.32%
Book Value per Share Growth-1.86%
Debt Growth-6.54%
R&D Expense Growth-6.55%
SGA Expenses Growth7.35%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 5,603,941,290, captures the company's total value, considering both debt and equity. Income quality, 0.55, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.06, gauges operational efficiency, while the research and development to revenue, 10.67%, highlights investment in innovation. The ratio of intangibles to total assets, 13.91%, indicates the value of non-physical assets, and capex to operating cash flow, -98.15%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value5,603,941,290
Income Quality0.55
Sales General and Administrative to Revenue0.06
Research and Development to Revenue10.67%
Intangibles to Total Assets13.91%
Capex to Operating Cash Flow-98.15%
Capex to Revenue-9.82%
Capex to Depreciation-226.80%
Stock-Based Compensation to Revenue1.03%
Graham Number14.85
Return on Tangible Assets17.51%
Graham Net Net0.05
Working Capital560,500,000
Tangible Asset Value689,900,000
Net Current Asset Value276,700,000
Average Receivables293,500,000
Average Payables108,350,000
Average Inventory338,900,000
Days Sales Outstanding109
Days Payables Outstanding70
Days of Inventory On Hand249
ROIC16.92%
ROE0.24%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 7.22, and the price to book ratio, 7.22, reflect the market's valuation relative to the company's book value. The price to sales ratio, 4.17, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 36.23, and price to operating cash flows, 22.71, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio7.22
Price to Book Ratio7.22
Price to Sales Ratio4.17
Price Cash Flow Ratio22.71
Price Earnings to Growth Ratio0.52
Enterprise Value Multiple19.19
Price Fair Value7.22
Price to Operating Cash Flow Ratio22.71
Price to Free Cash Flows Ratio36.23
Price to Tangible Book Ratio6.19
Enterprise Value to Sales4.71
Enterprise Value Over EBITDA19.82
EV to Operating Cash Flow47.09
Earnings Yield3.93%
Free Cash Flow Yield0.04%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Orion Oyj (ORNBV.HE) on the HEL in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 23.573 in 2024.

What is the ticker symbol of Orion Oyj stock?

The ticker symbol of Orion Oyj stock is ORNBV.HE.

What is company IPO date?

IPO date of Orion Oyj is 2004-10-07.

What is company current share price?

Current share price is 36.400 EUR.

What is stock market cap today?

The market cap of stock today is 5083704153.000.

What is PEG ratio in 2024?

The current 0.520 is 0.520 in 2024.

What is the number of employees in 2024?

In 2024 the company has 3698.